11859results about "Organic chemistry methods" patented technology

A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, or salt thereof, wherein R1, R2, L, X, Y, A, and B are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Embodiments of the present invention provide methods and intermediates for the large scale preparation of 2, 4, 6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl] benzamide hemisuccinate, as well as formulations and product forms prepared by these methods. Embodiments of the present invention further provide for the preparation of lamidetan acetate (2, 4, 6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl] benzamide acetate) and / or a pharmaceutical composition thereof, and / or the use of lamidetan acetate and formulations thereof in subcutaneous drug delivery.

The invention relates to a fused heteroaryl compound, a preparation method thereof and application of the fused heteroaryl compound in medicine. Specifically, the invention relates to a fused heteroaryl compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound in preparation of drugs for inhibiting KRAS amplification and / or mutant activity. Wherein each group in the general formula (I) is defined in the specification. # imgabs0 #

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

The invention discloses a hydroxytyrosol-ergothioneine eutectic crystal as well as a preparation method and application thereof, and belongs to the technical fields of medicines, foods, daily chemicals and the like. The invention provides a hydroxytyrosol-ergothioneine eutectic crystal. The X-ray powder diffraction pattern of the hydroxytyrosol-ergothioneine eutectic crystal has characteristic diffraction peaks at least corresponding to the positions where the 2 theta value is 4.21 degrees + / -0.2 degrees, 8.36 degrees + / -0.2 degrees, 12.29 degrees + / -0.2 degrees, 15.29 degrees + / -0.2 degrees, 19.40 degrees + / -0.2 degrees, 20.98 degrees + / -0.2 degrees, 23.12 degrees + / -0.2 degrees and 28.73 degrees + / -0.2 degrees. According to the hydroxytyrosol-ergothioneine eutectic, the melting point of hydroxytyrosol is increased, the hygroscopicity of hydroxytyrosol is remarkably reduced, and meanwhile the stability of hydroxytyrosol and ergothioneine is enhanced. In addition, after the ergothioneine hydroxytyrosol forms the eutectic crystal, the ergothioneine hydroxytyrosol can also play better anti-oxidation and anti-aging effects.

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.

The invention provides a pyrimidino heterocyclic compound as well as a pharmaceutical composition and application thereof. The invention provides a pyrimidino heterocyclic compound as shown in a formula I, and a stereoisomer, a tautomer, an atropisomer or a pharmaceutically acceptable salt of the pyrimidino heterocyclic compound. The compound disclosed by the invention has good proliferation inhibition activity on NCI-H358 cells, AsPC-1 cells and Capan-1 cells containing KRAS mutation, and has relatively weak proliferation inhibition activity on PC-9 cells wild in KRAS. # imgabs0 #

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

The invention discloses a method for extracting astaxanthin by using a biological enzyme, which comprises the following steps of: decomposing cell walls of haematococcus pluvialis at a certain temperature by using the biological enzyme, releasing astaxanthin from the haematococcus pluvialis, dissolving out the astaxanthin by using a certain solvent, and separating and purifying to obtain powdery astaxanthin. According to the method disclosed by the invention, wall breaking is carried out by combining ultrasound and biological enzyme, and a mixed solvent of ethanol and Tween 80 is adopted, so that the extraction rate of astaxanthin reaches 98.1%, the wall breaking time is shortened, and the efficiency is improved.

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I):tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

The invention discloses a preparation method of a GLP-1R agonist Orforglipron, which comprises the following reaction steps: carrying out four-step reaction on an oxopiperidine compound (1) and (4-fluoro-3, 5-dimethylphenyl) hydrazine (2) to obtain a compound 8, and carrying out seven-step reaction on 5-bromo-indolecarboxylic acid (9) to obtain a compound 17. Then, the compound 8 and a compound 17 are subjected to an acid amine condensation reaction, and Orforglipron (LY3502970) is obtained. The preparation method is relatively low in cost, easy to operate, relatively short in synthetic route and suitable for industrial production and application, and the total yield can reach 32%.

The disclosure provides solid forms of Compound A, as described herein. The disclosure also provides pharmaceutical compositions comprising the disclosed solid forms and methods of using the disclosed solid forms and pharmaceutical compositions (e.g., to treat cancer).

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The present invention addresses the problem of providing a method for producing olefins that can sufficiently remove polyamides from waste plastics. [Solution] The method for producing olefins according to the present invention includes a thermal decomposition step of thermally decomposing a waste plastic raw material containing polyolefins and polyamides to obtain a hydrocarbon stream, a separation step of separating a thermal decomposition product of the polyamides from the hydrocarbon stream that has undergone the thermal decomposition step, and a catalytic cracking step of catalytically cracking the hydrocarbon stream that has undergone the separation step in the presence of a catalyst containing zeolite to obtain olefins.

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-E) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention relates to the field of medicines. Specifically, the invention relates to a voltage-gated calcium channel alpha2delta subunit ligand containing a polycyclic gamma-aminobutyric acid structure as shown in a general formula I, a preparation method of the voltage-gated calcium channel alpha2delta subunit ligand and application of the voltage-gated calcium channel alpha2delta subunit ligand to treatment of chronic neuropathic pain, epilepsy and anxiety. # imgabs0 #

Provided are organometallic compounds including a ligand LA ofAlso provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.